← Back to Screener
Alnylam Pharmaceuticals, Inc. (ALNY)
Price$320.13
Favorite Metrics
Price vs S&P 500 (26W)-30.01%
Price vs S&P 500 (4W)0.08%
Market Capitalization$43.82B
P/E Ratio (Annual)139.66x
All Metrics
P/CF (Annual)83.61x
Book Value / Share (Quarterly)$5.96
P/TBV (Annual)2.64x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)52.98%
Cash Flow / Share (Quarterly)$3.52
Price vs S&P 500 (YTD)-18.80%
Gross Margin (TTM)81.64%
Net Profit Margin (TTM)8.45%
EPS (TTM)$2.25
10-Day Avg Trading Volume1.00M
EPS Excl Extra (TTM)$2.25
Revenue Growth (5Y)49.77%
EPS (Annual)$2.33
ROI (Annual)9.00%
Gross Margin (Annual)81.64%
Net Profit Margin (5Y Avg)-47.61%
Cash / Share (Quarterly)$21.97
P/E Basic Excl Extra (TTM)139.66x
Revenue Growth QoQ (YoY)84.95%
P/E Normalized (Annual)139.66x
ROA (Last FY)6.32%
Revenue Growth TTM (YoY)65.19%
EBITD / Share (TTM)$3.91
ROE (5Y Avg)-133.18%
Operating Margin (TTM)12.36%
Cash Flow / Share (Annual)$3.52
P/B Ratio55.52x
P/B Ratio (Quarterly)66.57x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)12.08x
Net Interest Coverage (TTM)3.25x
ROA (TTM)6.75%
EV / EBITDA (TTM)85.89x
EPS Incl Extra (Annual)$2.33
Current Ratio (Annual)2.76x
Quick Ratio (Quarterly)2.51x
3-Month Avg Trading Volume1.42M
52-Week Price Return38.91%
EV / Free Cash Flow (Annual)96.39x
P/E Incl Extra (TTM)139.66x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$3.38
P/S Ratio (Annual)11.80x
Asset Turnover (Annual)0.75x
52-Week High$495.55
Operating Margin (5Y Avg)-35.59%
EPS Excl Extra (Annual)$2.33
CapEx CAGR (5Y)-3.57%
Tangible BV CAGR (5Y)21.68%
26-Week Price Return-26.03%
Quick Ratio (Annual)2.51x
13-Week Price Return-10.12%
Total Debt / Equity (Annual)3.42x
Current Ratio (Quarterly)2.76x
Enterprise Value$44,858.303
Revenue / Share Growth (5Y)45.11%
Asset Turnover (TTM)0.80x
Book Value / Share Growth (5Y)-14.26%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)8.46x
Pretax Margin (Annual)8.70%
Cash / Share (Annual)$21.97
3-Month Return Std Dev38.90%
Gross Margin (5Y Avg)83.48%
Net Income / Employee (TTM)$0
ROE (Last FY)39.76%
Net Interest Coverage (Annual)0.88x
EPS Basic Excl Extra (Annual)$2.33
P/FCF (TTM)73.93x
Receivables Turnover (TTM)7.20x
EV / Free Cash Flow (TTM)96.39x
Total Debt / Equity (Quarterly)3.42x
EPS Incl Extra (TTM)$2.25
Receivables Turnover (Annual)7.20x
ROI (TTM)10.91%
P/S Ratio (TTM)11.80x
Pretax Margin (5Y Avg)-48.27%
Revenue / Share (Annual)$27.58
Tangible BV / Share (Annual)$3.73
Forward P/E47.86x
Price vs S&P 500 (52W)9.08%
P/E Ratio (TTM)139.66x
Year-to-Date Return-16.16%
5-Day Price Return3.77%
EPS Normalized (Annual)$2.33
ROA (5Y Avg)-13.41%
Net Profit Margin (Annual)8.45%
Month-to-Date Return0.76%
Cash Flow / Share (TTM)$-3.62
EBITD / Share (Annual)$3.88
Operating Margin (Annual)12.36%
LT Debt / Equity (Annual)3.14x
P/CF (TTM)83.61x
ROI (5Y Avg)-40.42%
P/E Excl Extra (TTM)139.66x
LT Debt / Equity (Quarterly)3.14x
EPS Basic Excl Extra (TTM)$2.25
P/TBV (Quarterly)5.56x
P/B Ratio (Annual)66.57x
Inventory Turnover (TTM)8.46x
Pretax Margin (TTM)8.70%
Book Value / Share (Annual)$5.96
Price vs S&P 500 (13W)-10.80%
Beta0.36x
P/FCF (Annual)94.15x
Revenue / Share (TTM)$27.25
ROE (TTM)90.35%
52-Week Low$225.84
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.97
3.97
4.00
3.94
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ALNYAlnylam Pharmaceuticals, Inc. | 11.80x | 65.19% | 81.64% | — | $320.13 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Alnylam Pharmaceuticals is a leader in RNA interference (RNAi) therapeutics with five FDA-approved drugs generating revenue across rare genetic diseases and cardio-metabolic indications. The company has an expanding pipeline in genetic medicines, hepatic infectious diseases, and CNS/ocular diseases, with multiple programs in clinical development. Partnership upfront fees and upcoming milestone and royalty payments from collaborations provide additional cash generation and revenue diversification beyond its commercial portfolio.